PainReform Ltd. stock declines amid market weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 05 Dec 25
PainReform Ltd. shares fell by 6.86% and crossed down the 5-day SMA, reflecting broader market trends.
The company has initiated the development plan for OcuRing-K, targeting a significant share of the global cataract surgery market, which exceeds $9 billion annually. This innovative therapy aims to enhance postoperative recovery for millions of patients.
Despite the promising developments, the stock's decline indicates investor caution, possibly influenced by overall market conditions and sector performance.
Analyst Views on PRFX
About PRFX
PRF Technologies Ltd is an Israel-based company engaged primarily in pharmaceutical sector. The Company is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The Company also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
